Gemtesa 75 MG tablet 90S
Ended Awarded Last action
- Contract number
- SPE2DR26F9R2J
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,218
Award facts
- Contract value 100% obligated
- $20,217.57 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $20,217.57 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 90 tablets of Gemtesa 75 mg, with an ultimate completion date of January 23, 2026. This non-set-aside contract was competitively awarded and represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at up to $999,999,999.00 through December 2026), which serves as a comprehensive pharmaceutical supply vehicle for military healthcare programs worldwide. The place of performance is listed as AmerisourceBergen's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (which rebranded from AmerisourceBergen), is a major pharmaceutical distributor and critical vendor for federal medical procurement supporting military and veteran healthcare systems.
Gemtesa (mirabegron) is a beta-3 agonist medication primarily used to treat overactive bladder symptoms. This delivery order reflects the Defense Logistics Agency's ongoing reliance on AmerisourceBergen's pharmaceutical distribution capabilities to supply specialty medications and medical commodities to defense healthcare facilities. The company's federal contract portfolio demonstrates its extensive experience fulfilling government requirements across multiple therapeutic domains, from specialty medications to vaccines and medical devices, consistently leveraging firm fixed-price arrangements to deliver predictable costs for federal customers.
Quick answers
Who was awarded contract SPE2DR26F9R2J?
SPE2DR26F9R2J was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26F9R2J worth?
The government has obligated $20,218 on SPE2DR26F9R2J.
Is contract SPE2DR26F9R2J an order under another contract?
Yes. SPE2DR26F9R2J is a delivery order under SPE2DR25D3020, an indefinite delivery contract.
Was contract SPE2DR26F9R2J competed?
The extent of competition for SPE2DR26F9R2J was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award